Post-Ischemic Brain Neurodegeneration in the Form of Alzheimer's Disease Proteinopathy: Possible Therapeutic Role of Curcumin

Nutrients. 2022 Jan 7;14(2):248. doi: 10.3390/nu14020248.

Abstract

For thousands of years, mankind has been using plant extracts or plants themselves as medicinal herbs. Currently, there is a great deal of public interest in naturally occurring medicinal substances that are virtually non-toxic, readily available, and have an impact on well-being and health. It has been noted that dietary curcumin is one of the regulators that may positively influence changes in the brain after ischemia. Curcumin is a natural polyphenolic compound with pleiotropic biological properties. The observed death of pyramidal neurons in the CA1 region of the hippocampus and its atrophy are considered to be typical changes for post-ischemic brain neurodegeneration and for Alzheimer's disease. Additionally, it has been shown that one of the potential mechanisms of severe neuronal death is the accumulation of neurotoxic amyloid and dysfunctional tau protein after cerebral ischemia. Post-ischemic studies of human and animal brains have shown the presence of amyloid plaques and neurofibrillary tangles. The significant therapeutic feature of curcumin is that it can affect the aging-related cellular proteins, i.e., amyloid and tau protein, preventing their aggregation and insolubility after ischemia. Curcumin also decreases the neurotoxicity of amyloid and tau protein by affecting their structure. Studies in animal models of cerebral ischemia have shown that curcumin reduces infarct volume, brain edema, blood-brain barrier permeability, apoptosis, neuroinflammation, glutamate neurotoxicity, inhibits autophagy and oxidative stress, and improves neurological and behavioral deficits. The available data suggest that curcumin may be a new therapeutic substance in both regenerative medicine and the treatment of neurodegenerative disorders such as post-ischemic neurodegeneration.

Keywords: amyloid; brain ischemia; curcumin; dementia; neurodegeneration; neuroprotection; tau protein.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / etiology
  • Amyloid / drug effects
  • Amyloid / metabolism
  • Animals
  • Apoptosis / drug effects
  • Atrophy / etiology
  • Biological Availability
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Brain Edema / drug therapy
  • Brain Ischemia / complications*
  • Brain Ischemia / drug therapy
  • Curcumin / chemistry
  • Curcumin / pharmacokinetics
  • Curcumin / pharmacology*
  • Disease Models, Animal
  • Gastrointestinal Microbiome / physiology
  • Gerbillinae
  • Hippocampus / pathology
  • Humans
  • Mice
  • Neuroinflammatory Diseases / drug therapy
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacokinetics
  • Neuroprotective Agents / pharmacology*
  • Oxidative Stress / drug effects
  • Rats
  • tau Proteins / drug effects
  • tau Proteins / metabolism

Substances

  • Amyloid
  • Neuroprotective Agents
  • tau Proteins
  • Curcumin